.png)
Eyes on Clinical Trial Data, Supply Upgrades, and Patent Litigation
The news this week was full of "Ups-n-Downs." We've noted a few here and know there were more surprises with clinical data results, M&A, and
top of page
Eyes on Pharma
Check-out What Intel Caught our Eye
Jana Chisholm
Nov 24, 20233 min read
Eyes on Casgevy, Pfizer & More
Some of this week's news includes Casgevy Approval, Novo's REDEFINE 4 Trial, , new Manufacturing plant and more.
Jana Chisholm
Nov 17, 20233 min read
Eyes On Current Events
While we've been curating 3Q23 Results reports, we've had eyes on drug approvals, Business Development activities, & even some patent ...
Robin Bateman
Oct 26, 20236 min read
Eyes on Obesity & Weight Loss
We found ourselves looking closer at the disease, the history of weight loss medications, and the potential impact of effective weight manag
Robin Bateman
Sep 6, 20236 min read
Eyes On - The IRA Drug Price Negotiations
This week we had Eyes On the upcoming IRA Drug pricing negotiations - here's some of the news and views we saw.
Robin Bateman
Jul 10, 20231 min read
Medical Conferences
We have Eyes on Pharma Conferences this week. Don't forget to check PharmaTell Studio for the latests Planners, Insights, and Key Takes.
Robin Bateman
Mar 13, 20233 min read
Eyes on the MedTechDev Sector
The MedTech sector seemed to take the brunt of the 2022 market decline but looking to forward there may be light at the end of the tunnel.
Robin Bateman
Jan 25, 20234 min read
Eyes on the News Snippets In Our View
We’ve had Eyes On – Some of the Post Holiday /Pre-Earnings News Snippets As the companies and the markets gear up for Results, tucked in...
Robin Bateman
Dec 28, 20222 min read
Eyes On - Reviews & Previews for BioPharma & MedTech
I've got Eyes On the Review / Preview Articles for the Healthcare Industry. It's interesting to see a snapshot of 2022 and some predictions
Robin Bateman
Nov 26, 20222 min read
Eyes On Current Events
After all the quarterly results reporting, we've had eyes on product approvals, resubmissions, and a withdrawal.
Robin Bateman
Aug 18, 20226 min read
Heartburn from Zantac
This week PharmaTell had Eyes On: Heartburn – the kind caused by the upcoming Zantac litigation & resulting market jitters.
Robin Bateman
Jul 22, 20223 min read
Amazon + One Medical
This week we had Eyes On Amazon & One Medical – as did many of you, I am sure. We saw the news and, of course, had a variety of thoughts...
jroele
Jul 20, 20221 min read
PharmaTell is in the Top 10!
We are excited to announce PharmaTech Outlook selected us as one of the Top 10 Pharma Marketing Services Companies in Europe – 2022!
Robin Bateman
Jul 10, 20222 min read
Pharma CI Europe Conference +FDA Updates + Clinical Data Readouts
The PharmaTell Team has had Eyes On — The Pharma CI Europe Conference, US FDA Regulatory Updates. Plus 2H22 Clinical Data Readouts.
Robin Bateman
Jun 7, 20222 min read
Good News for PPD Patients + ASCO Updates
As with most of you I'm sure - this week the PharmaTell Team had Eyes on ASCO + positive data for postpartum depression patients.
Robin Bateman
May 22, 20223 min read
US Baby Formula Shortage - A Complicated Story
PharmaTell had Eyes on the US Baby Formula Shortage this week. I was curious as to how this happened
Robin Bateman
May 15, 20222 min read
Product Approvals, Delays & Disappointments
This was a busy week for Healthcare with 1Q22 Results. The PharmaTell Team had eyes on some of the US FDA decisions + Roche's SKYSCRAPER-01
Robin Bateman
May 8, 20222 min read
Quarterly Results, Biogen & Conference Planning
The PharmaTell Team has been busy curating Quarterly Results reports & upcoming conference planners + keeping up with Biogen next steps.
Robin Bateman
Apr 20, 20222 min read
AACR Updates & CAR-T Overview
This week the team has been enjoying the spring holidays and keeping their eyes on some of the recent news from AACR and learning a bit more
jroele
Apr 4, 20222 min read
PharmaTell Studio Upgrades
We are excited to share the latest upgrades to PharmaTell Studio making it even easier for you to keep your eyes on you & your competition.
bottom of page